Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:activeDuring |
Tolvaptan
|
| gptkbp:availableSizes |
15 mg once daily
30 mg once daily |
| gptkbp:clinicalTrials |
Phase III
Heart failure treatment Long-term treatment Short-term treatment Cirrhosis management Hyponatremia management |
| gptkbp:contraindication |
Fatigue
Headache Constipation Electrolyte imbalance Liver function abnormalities Severe liver impairment Hypersensitivity to tolvaptan Anuria |
| gptkbp:date |
2010-01-20
|
| gptkbp:dosageForm |
Tablet
|
| gptkbp:drugInterdiction |
Diuretics
True CYP3A4 inhibitors CYP3A4 inducers Vasopressin receptor antagonist |
| gptkbp:formulation |
Film-coated tablet
|
| gptkbp:healthcare |
Stay hydrated
Monitor sodium levels Report any unusual symptoms |
| https://www.w3.org/2000/01/rdf-schema#label |
Samsca
|
| gptkbp:lastProduced |
gptkb:United_States
|
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:marketedAs |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:packaging |
Blister pack
|
| gptkbp:relatedPatent |
Heart failure
Cirrhosis SIADH |
| gptkbp:researchFocus |
Chronic kidney disease
Hyponatremia treatment Vasopressin receptor antagonism |
| gptkbp:route |
Oral
|
| gptkbp:sideEffect |
Diarrhea
Nausea Dry mouth Thirst |
| gptkbp:skills |
15 mg
30 mg |
| gptkbp:storage |
Room temperature
|
| gptkbp:triggerType |
Vasopressin receptor inhibition
|
| gptkbp:usedFor |
Hyponatremia
|